Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

AGP cuts ReShape Lifesciences PT to $5.50 from $10.25

Alliance Global Partners slashed its price target for ReShape Lifesciences (NASDAQ:RSLS) to $5.50 from $10.25 but maintained its “buy” rating, citing the company’s fourth quarter results. The stock closed at $1.35 on...

March 29, 2022

Executive Moves

Long-time research analyst Anthony Petrone joins Mizuho Americas

Anthony Petrone Mizuho Americas hired Anthony Petrone as a managing director, senior medical devices, diagnostics and therapeutics equity research analyst. Mr. Petrone has more than 16 years of experience in...

March 28, 2022

Markets

Analysts reduce MEI Pharma PTs; Stifel cuts MEI to hold from buy

Stifel downgraded MEI Pharma (NASDAQ:MEIP) to “hold” from “buy” and reduced its price target to $2 from $6 after the FDA discouraged a regulatory filing based on single-arm Phase 2 TIDAL study data, despite previous...

March 25, 2022

Markets

Maxim starts Longeveron at buy; PT $14

Maxim Group initiated coverage of Longeveron (NASDAQ:LGVN) with a “buy” rating and $14 price target. The stock closed at $6.52 on March 23. Longeveron is developing a medicinal signaling cell therapy, Lomecel-B, for...

March 24, 2022

Markets

Maxim starts HCW Biologics at buy; PT $4

Maxim Group initiated coverage of HCW Biologics (NASDAQ:HCWB) with a “buy” rating and price target of $4. The stock closed at $2.28 on March 23. HCW Biologics is addressing inflammaging; the chronic, sterile, low-grade...

March 24, 2022

Executive Moves

Long-time healthcare investment banker Jim Alfaro joins JMP

Jim Alfaro has joined JMP Securities as a managing director, healthcare investment banker, after a nearly 15-year stint with Maxim Group.

March 22, 2022

Developments

Palisade Bio receives FDA okay for Phase 3 trial for return of bowel function

Palisade Bio (NASDAQ:PALI) received a “study may proceed” letter from the FDA for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing...

March 22, 2022

Markets

HCW starts BioAtla at buy; PT $25

H.C. Wainwright launched coverage of BioAtla (NASDAQ:BCAB) with a “buy” rating and $25 price target. The stock closed at $5.77 on March 18. BioAtla is a clinical-stage biopharmaceutical company developing novel...

March 21, 2022

Executive Moves

Long-time healthcare investment banker Kee Colen joins Cantor Fitzgerald

Kee Colen has joined Cantor Fitzgerald as a managing director, healthcare investment banking, from Raymond James.

March 21, 2022

Markets

BTIG cuts Talis Biomedical to sell; PT $1

BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “sell” from “neutral” with a price target of $1, citing a delay in the beta-phase rollout of the Talis One COVID-19 diagnostic, which was planned for the first quarter...

March 18, 2022

Developments

Cytovale IntelliSep study data to risk-stratify patients published in PLOS ONE

Closely-held Cytovale announced that a new study of its investigational IntelliSep test has been published in the peer-reviewed journal, PLOS ONE. The study demonstrated that the IntelliSep test has the potential to...

March 17, 2022

Markets

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

Raymond James downgraded Cardiol Therapeutics (TSX:CRDL) to “market perform” from “outperform” and trimmed its price target to $4 (Canadian) from $5, citing a slower than expected enrollment in Cardiol’s LANCER clinical...

March 16, 2022

AGP cuts ReShape Lifesciences PT to $5.50 from $10.25

Long-time research analyst Anthony Petrone joins Mizuho Americas

Analysts reduce MEI Pharma PTs; Stifel cuts MEI to hold from buy

Maxim starts Longeveron at buy; PT $14

Maxim starts HCW Biologics at buy; PT $4

Long-time healthcare investment banker Jim Alfaro joins JMP

Palisade Bio receives FDA okay for Phase 3 trial for return of bowel function

HCW starts BioAtla at buy; PT $25

Long-time healthcare investment banker Kee Colen joins Cantor Fitzgerald

BTIG cuts Talis Biomedical to sell; PT $1

Cytovale IntelliSep study data to risk-stratify patients published in PLOS ONE

Raymond James cuts Cardiol Therapeutics to MP; PT to $4 (Canadian)

General

More